GlassScriptPhysician profile
Gregory J Esslinger
NPI 1164784377
$2,419.58
in general payments reported to CMS, 2019-2025
41 companies · $32.52 in 2025
The $32.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $123 · 2021: $433 · 2022: $552 · 2023: $460 · 2024: $642 · 2025: $32.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $348.98 | 2019-2024 | Qelbree |
| Abbvie INC. | $334.00 | 2021-2024 | |
| Pfizer INC. | $219.23 | 2019-2024 | |
| Amgen INC. | $168.16 | 2020-2024 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $162.79 | 2022-2023 | Hetlioz, Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.10 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $88.19 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Jazz Pharmaceuticals INC. | $71.46 | 2019-2021 | |
| Lilly USA, LLC | $68.73 | 2021-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $56.06 | 2019-2024 | |
| Exact Sciences Corporation | $47.13 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.65 | 2020-2022 | |
| Axsome Therapeutics, INC. | $46.05 | 2023-2025 | Auvelity |
| Medtronic, INC. | $44.56 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $41.78 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Esslinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.